Association of the PPAR-γ gene with altered glucose levels and psychosis profile in schizophrenia patients exposed to antipsychotics

Psychiatry Investigation

Volumn 11, Issue 2, 2014, Pages 179-185

  Liu, Yun Ru ^a   Hu, Tsung Ming ^b   Lan, Tsuo Hung ^c,d,e   Chiu, Hsien Jane ^c,f,g   Chang, Yung Han ^c   Chen, Shuo Fei ^h,i   Yu, Yen Hsin ^j   Chen, Cheng Chung ^k   Loh, El Wui ^k  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b YULI VETERANS HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^e NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^f CHUNG HWA UNIVERSITY OF MEDICAL TECHNOLOGY   (Taiwan)

^g MIN SHENG GENERAL HOSPITAL   (Taiwan)

^h YU DA UNIVERSITY   (Taiwan)

ⁱ NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^j INSTITUTE OF MOLECULAR BIOLOGY   (Taiwan)

^k Superintendent of Kaohsiung Kai Syuan Psychiatric Hospital   (Taiwan)

more..

Author keywords

Glucose; PPAR gene; Psychosis; Schizophrenia

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIVER X RECEPTOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPING TECHNIQUE; GLUCOSE BLOOD LEVEL; HUMAN; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; OBESITY; POSITIVE AND NEGATIVE SYNDROME SCALE; PSYCHOSIS; SCHIZOPHRENIA; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84900309738     PISSN: 17383684     EISSN: 19763026     Source Type: Journal    
DOI: 10.4306/pi.2014.11.2.179     Document Type: Article

References (30)

1. Girgis RR, Javitch JA, Lieberman JA. Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway. Mol Psychiatry 2008;13:918-929.
2. Spelman LM, Walsh PI, Sharifi N, Collins P, Thakore JH. Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabet Med 2007;24:481-485.
3. Carpenter WT Jr. Clinical constructs and therapeutic discovery. Schizophr Res 2004;72:69-73.
4. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 1999;35:51-68.
5. Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med 2004;10:355-361.
6. Dreyer C, Krey G, Keller H, Givel F, Helftenbein G, Wahli W. Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell 1992;68:879-887.
7. Jones PS, Savory R, Barratt P, Bell AR, Gray TJ, Jenkins NA, et al. Chromosomal localisation, inducibility, tissue-specific expression and strain differences in three murine peroxisome-proliferator-activated-receptor genes. Eur J Biochem 1995;233:219-226.
8. Lemberger T, Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Annu Rev Cell Dev Biol 1996;12:335-363.
9. He W, Barak Y, Hevener A, Olson P, Liao D, Le J, et al. Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci U S A 2003;100:15712-15717.
10. Koutnikova H, Cock TA, Watanabe M, Houten SM, Champy MF, Dierich A, et al. Compensation by the muscle limits the metabolic consequences of lipodystrophy in PPAR gamma hypomorphic mice. Proc Natl Acad Sci U S A 2003;100:14457-14462.
11. Chen CH, Lu ML, Kuo PH, Chen PY, Chiu CC, Kao CF, et al. Gender differences in the effects of peroxisome proliferator-activated receptor γ2 gene polymorphisms on metabolic adversity in patients with schizophrenia or schizoaffective disorder. Prog Neuropsychopharmacol Biol Psychiatry 2011;5:239-245.
12. Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes of BioMedical Research, Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PI, et al. Genomewide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007;316:1331-1336.
13. Daynes RA, Jones DC. Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2002;2:748-759.
14. Ijpenberg A, Jeannin E, Wahli W, Desvergne B. Polarity and specific sequence requirements of peroxisome proliferator-activated receptor (PPAR)/retinoid X receptor heterodimer binding to DNA. A functional analysis of the malic enzyme gene PPAR response element. J Biol Chem 1997;272:20108-20117.
15. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 1992;358:771-774.
16. Goodman AB. Three independent lines of evidence suggest retinoids as causal to schizophrenia. Proc Natl Acad Sci U S A 1998;95:7240-7244.
17. Xiao JH, Durand B, Chambon P, Voorhees JJ. Endogenous retinoic acid receptor (RAR)-retinoid X receptor (RXR) heterodimers are the major functional forms regulating retinoid-responsive elements in adult human keratinocytes. Binding of ligands to RAR only is sufficient for RAR-RXR heterodimers to confer ligand-dependent activation of hRAR beta 2/RARE (DR5). J Biol Chem 1995;270:3001-3011.
18. Cheng JJ, Ho H, Chang CJ, Lane HY, Hu HG. Positive and negative syndrome scale (PANSS): Establishment and reliability study of a mandarin Chinese language version. Chin Psychiaty 1996;10:251-258.
19. Greene ME, Blumberg B, McBride OW, Yi HF, Kronquist K, Kwan K, et al. Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expr 1995;4:281-299.
20. McClelland S, Shrivastava R, Medh JD. Regulation of translational efficiency by disparate 5' UTRs of PPARgamma splice variants. PPAR Res 2009;2009:193413.
21. Fajas L, Auboeuf D, Raspé E, Schoonjans K, Lefebvre AM, Saladin R, et al. The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem 1997;272:18779-18789.
22. Wu MC, Kraft P, Epstein MP, Taylor DM, Chanock SJ, Hunter DJ, et al. Powerful SNP-set analysis for case-control genome-wide association studies. Am J Hum Genet 2010;86:929-942.
23. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000;26:76-80.
24. Tonjes A, Scholz M, Loeffler M, Stumvoll M. Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma with Pre-diabetic phenotypes: meta-analysis of 57 studies on nondiabetic individuals. Diabetes Care 2006;29:2489-2497.
25. Allen NC, Bagade S, McQueen MB, Ioannidis JP, Kavvoura FK, Khoury MJ, et al. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat Genet 2008; 40:827-834.
26. Xu MQ, St Clair D, He L. Meta-analysis of association between ApoE epsilon4 allele and schizophrenia. Schizophr Res 2006;84:228-235.
27. Anthopoulos PG, Hamodrakas SJ, Bagos PG. Apolipoprotein E polymorphisms and type 2 diabetes: a meta-analysis of 30 studies including 5423 cases and 8197 controls. Mol Genet Metab 2010;100:283-291.
28. Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB, et al. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 2001;7:161-171.
29. Kirkpatrick B, Galderisi S. Deficit schizophrenia: an update. World Psychiatry 2008;7:143-147.
30. Yates KF, Sweat V, Yau PL, Turchiano MM, Convit A. Impact of metabolic syndrome on cognition and brain: a selected review of the literature. Arterioscler Thromb Vasc Biol 2012;32:2060-2067.